Emcure Pharmaceuticals Limited (NSE:EMCURE)
India · Delayed Price · Currency is INR 2,334.40
+102.00 (4.57%)
Nov 12, 2026, 3:30 PM IST
Emcure Pharmaceuticals Financials Overview
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Revenue Revenue Growth | 102,341 | 92,035 | 78,960 | 66,583 | 59,858 | 58,554 |
Revenue Growth | 21.13% | 16.56% | 18.59% | 11.23% | 2.23% | 16.33% |
Gross Profit Gross Profit Growth | 59,628 | 54,562 | 46,735 | 41,225 | 36,673 | 35,690 |
Operating Income Operating Income Growth | 15,985 | 13,738 | 10,847 | 9,173 | 9,214 | 10,855 |
Net Income Net Income Growth | 10,935 | 9,244 | 6,813 | 4,982 | 5,320 | 6,622 |
Earnings Per Share EPS Growth | 57.64 | 48.77 | 36.43 | 27.54 | 29.42 | 36.62 |
EPS Growth | 37.65% | 33.88% | 32.27% | -6.38% | -19.66% | 68.90% |
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
India India Growth | 42,515 | 40,270 | 36,597 | 32,149 | 31,818 | 32,047 |
ROW ROW Growth | 21,850 | 18,399 | 15,105 | 10,919 | 8,872 | 10,745 |
Europe Europe Growth | - | 18,498 | 14,738 | 14,236 | 11,873 | 8,968 |
North America North America Growth | - | 14,869 | 12,520 | 9,279 | 7,294 | 6,795 |
Total Total Growth | 102,340 | 92,035 | 78,960 | 66,583 | 59,858 | 58,554 |
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash & Investments Cash & Investments Growth | 1,473 | 1,367 | 2,316 | 4,687 | 4,468 | 1,628 |
Total Debt Total Debt Growth | 17,568 | 15,212 | 10,227 | 23,350 | 23,343 | 22,172 |
Net Cash (Debt) Net Cash Growth | -16,095 | -13,846 | -7,912 | -18,663 | -18,875 | -20,544 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -84.83 | -73.05 | -42.30 | -103.18 | -104.37 | -113.59 |
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Cash Flow Operating Cash Flow Growth | 13,696 | 9,435 | 8,517 | 10,972 | 7,469 | 7,682 |
Capital Expenditures CapEx Growth | -4,771 | -3,606 | -2,218 | -2,758 | -3,906 | -3,782 |
Free Cash Flow Free Cash Flow Growth | 8,925 | 5,830 | 6,299 | 8,215 | 3,563 | 3,900 |
Free Cash Flow Growth | 75.92% | -7.45% | -23.32% | 130.58% | -8.65% | -32.65% |
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Gross Margin | 58.26% | 59.28% | 59.19% | 61.92% | 61.27% | 60.95% |
Operating Margin | 15.62% | 14.93% | 13.74% | 13.78% | 15.39% | 18.54% |
Pretax Margin | 14.60% | 13.99% | 12.30% | 10.92% | 12.48% | 16.61% |
Profit Margin | 10.69% | 10.04% | 8.63% | 7.48% | 8.89% | 11.31% |
FCF Margin | 8.72% | 6.33% | 7.98% | 12.34% | 5.95% | 6.66% |
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Nov '26 Nov 12, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Dividend Per Share Dividend Per Share Growth | 3.600 | 3.600 | 3.000 | - | 2.000 | 3.000 |
Dividend Per Share Growth | 0% | 20.00% | - | - | -33.33% | 200.00% |
Dividend Yield | 0.15% | 0.23% | 0.28% | - | - | - |
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Nov '26 Nov 12, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
PE Ratio | 40.50 | 32.72 | 29.82 | - | - | - |
Forward PE | 30.19 | 27.50 | 24.17 | - | - | - |
P/FCF Ratio | 49.05 | 51.89 | 32.26 | - | - | - |
PS Ratio | 4.28 | 3.29 | 2.57 | - | - | - |